NCT01668524View on ClinicalTrials.gov

ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

ATS907

Single dose of each of three increasing concentrations

Trial Locations (1)

90701

Sall Research Medical Center, Artesia

Sponsors

Lead Sponsor

Altheos, Inc.
All Listed Sponsors
lead

Altheos, Inc.

INDUSTRY

NCT01668524 - ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects | Biotech Hunter | Biotech Hunter